Characterization of Clinical and Environmental Isolates of <i>Cryptococcus neoformans</i>/<i>Cryptococcus gattii</i> Complex Maintained in Yeast Culture Collection in São Paulo, Brazil

Abstract

Objective: As isolates of Cryptococcus are frequently kept collection stocks in institutions, sometimes without proper characterization, we sought to determine the genotype profiles, protease and phospholipase activities "in vitro" and the susceptibility testing for azoles and amphotericin B. Methodology: 84 isolates from several regions of Brazil (40 samples from clinical origin and 44 isolates from environmental origin) were maintained at the microorganism's bank of the Biomedical Science Institute (ICB-USP) of the São Paulo University, in São Paulo, Brazil. This isolates was submitted fungal strains determination, DNA extraction and purification, determination of genotype by URA5 gene RFLP of CGB-positive isolates, protease and phospholipase activity and susceptibility to antifungals. Results: Of six CGB positive isolates tested by RFLP-PCR, only four presented a genomic profile consistent C.

<i>Cryptococcus</i> and <i>Cryptococcosis</i> in Human and Animal Model: An Overview

“…In recent years many researches and clinical trials have led to improvement, such as disease prevention. An accurate diagnosis, and correct therapy have collaborated in the treatment of this disease [26]. One of the main components of the C. neoformans and C. gattii capsule is glucuronoxylomannan (GXM), detected by the antigen agglutination test (CALAT) [27].…”